CORESTEMCHEMON Inc. (KOSDAQ:166480)
South Korea · Delayed Price · Currency is KRW 1,587.00
-14.00 (-0.87%)
At close: Nov 6, 2026
CORESTEMCHEMON Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 18,292 | 20,159 | 28,762 | 33,657 | 45,878 | 30,240 |
Revenue Growth | -26.34% | -29.91% | -14.54% | -26.64% | 51.71% | 14.73% |
Gross Profit Gross Profit Growth | -4,903 | -4,146 | -1,207 | 3,411 | 15,149 | 7,986 |
Operating Income Operating Income Growth | -20,885 | -21,267 | -22,019 | -19,713 | -6,352 | -10,550 |
Net Income Net Income Growth | -27,807 | -26,833 | -26,252 | -17,672 | -2,257 | -6,999 |
Earnings Per Share EPS Growth | -681.82 | -903.00 | -1124.18 | -837.00 | -533.10 | -642.51 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Non-Clinical Trial Agency Division Non-Clinical Trial Agency Division Growth | 18,292 | 19,971 | 27,641 | 32,017 | 40,868 | 29,140 |
Cell Therapy Pharmaceutical Sector Cell Therapy Pharmaceutical Sector Growth | - | 187.62 | 1,561 | 2,120 | 5,489 | 1,572 |
Unallocated Adjustments Unallocated Adjustments Growth | - | - | -440 | -480 | -480 | -471.4 |
Total Total Growth | 18,292 | 20,159 | 28,762 | 33,657 | 45,878 | 30,240 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 4,435 | 8,140 | 4,501 | 2,707 | 2,592 | 68,748 |
Total Debt Total Debt Growth | 37,649 | 38,898 | 46,826 | 32,771 | 18,436 | 27,639 |
Net Cash (Debt) Net Cash Growth | -33,214 | -30,758 | -42,325 | -30,064 | -15,844 | 41,109 |
Net Cash Growth | - | - | - | - | - | -43.94% |
Net Cash Per Share Net Cash Per Share Growth | -814.20 | -1034.81 | -1812.42 | -1214.07 | -878.67 | 2276.90 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -10,011 | -13,867 | -21,118 | -15,697 | -8,273 | -7,646 |
Capital Expenditures CapEx Growth | -1,378 | -2,056 | -22,706 | -9,174 | -9,078 | -15,043 |
Free Cash Flow Free Cash Flow Growth | -11,389 | -15,922 | -43,824 | -24,870 | -17,351 | -22,690 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -26.80% | -20.57% | -4.20% | 10.13% | 33.02% | 26.41% |
Operating Margin | -114.18% | -105.50% | -76.56% | -58.57% | -13.85% | -34.89% |
Pretax Margin | -152.16% | -132.91% | -108.83% | -52.52% | 7.43% | -14.63% |
Profit Margin | -152.02% | -133.11% | -91.27% | -52.51% | -4.92% | -23.14% |
FCF Margin | -62.26% | -78.98% | -152.36% | -73.89% | -37.82% | -75.03% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 42.15 | 42.15 | 42.15 | 42.15 | 42.15 |
PS Ratio | 3.88 | 4.07 | 3.29 | 4.31 | 5.57 | 9.71 |